Cellectar Biosciences Inc (CLRB)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.15-6.50%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · CLRB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
CLRB — earnings miss
Dated 2026-08-13
Results of Operations and Financial Condition. On August 13, 2026, we issued a press release announcing our financial results for the quarter ended June 30, 2026, and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.
Why it matters: The filing plan depends on FDA review and trial progress. A clear path would support the approval case.
Supportive ifThe company keeps its mid-2027 filing plan and reports no new FDA requests that change the timing.
Worry ifThe company moves the filing past mid-2027 or reports new FDA requirements that delay it.
Why it matters: Early results will show whether CLR 125 can move beyond its first trial stage in triple-negative breast cancer.
Watch forThe company reports dose and safety data. No safety issue limits treatment. Treated patients also show tumor response.
Also watch forThe company reports a serious safety issue, no tumor responses, or a pause in trial dosing.
Why it matters: This report can show whether the Phase 3 plan and cash runway remain on track. The company is loss-making and has high risk signals.
Watch forThe update confirms Phase 3 site work is progressing and keeps the cash runway into Q2 2027.
Also watch forThe update reports a trial delay, a shorter cash runway, or a need for added funding.
Why it matters: The trial is a key step toward the planned mid-2027 FDA filing. A timely start would support that path.
Supportive ifThe company reports that the first patient received a dose in early 2027, as planned.
Worry ifThe first patient has not received a dose by the end of Q1 2027, or the company delays the trial start.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$162 on $10,000 · ±1.6% | How much price usually moves either way. |
| Bad day | $754 loss on $10,000 · 7.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,228 loss on $10,000 · 72.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.